CN104244982A - 酪氨酸激酶抑制剂组合及其用途 - Google Patents

酪氨酸激酶抑制剂组合及其用途 Download PDF

Info

Publication number
CN104244982A
CN104244982A CN201380018928.6A CN201380018928A CN104244982A CN 104244982 A CN104244982 A CN 104244982A CN 201380018928 A CN201380018928 A CN 201380018928A CN 104244982 A CN104244982 A CN 104244982A
Authority
CN
China
Prior art keywords
tyrosine kinase
combination
met
fgfr
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380018928.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·提耶德
A·博克勒
F·哈宾斯基
S·桑哈维
D·杰弗里
C·威尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104244982A publication Critical patent/CN104244982A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380018928.6A 2012-04-03 2013-04-01 酪氨酸激酶抑制剂组合及其用途 Pending CN104244982A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261619502P 2012-04-03 2012-04-03
US61/619,502 2012-04-03
PCT/US2013/034759 WO2013151913A1 (en) 2012-04-03 2013-04-01 Tyrosine kinase inhibitor combinations and their use

Publications (1)

Publication Number Publication Date
CN104244982A true CN104244982A (zh) 2014-12-24

Family

ID=48184451

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380018928.6A Pending CN104244982A (zh) 2012-04-03 2013-04-01 酪氨酸激酶抑制剂组合及其用途

Country Status (11)

Country Link
US (1) US20150051210A1 (enExample)
EP (1) EP2833917A1 (enExample)
JP (1) JP2015512447A (enExample)
KR (1) KR20140146086A (enExample)
CN (1) CN104244982A (enExample)
AU (1) AU2013243737B2 (enExample)
CA (1) CA2866321A1 (enExample)
IN (1) IN2014DN07410A (enExample)
MX (1) MX2014011987A (enExample)
RU (1) RU2014143213A (enExample)
WO (1) WO2013151913A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3014202T3 (en) * 2014-03-26 2025-04-21 Astex Therapeutics Ltd Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors
KR20170036037A (ko) * 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
WO2017104739A1 (ja) 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005038537A1 (de) 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
DK1966214T3 (en) 2005-12-21 2017-02-13 Janssen Pharmaceutica Nv TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
KR20090071612A (ko) 2006-10-23 2009-07-01 에스지엑스 파마슈티컬스, 인코포레이티드 단백질 키나제 조정제로서의 바이시클릭 트리아졸
MX2009005144A (es) * 2006-11-22 2009-05-27 Incyte Corp Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa.
JP4994044B2 (ja) * 2007-01-05 2012-08-08 シェブロンジャパン株式会社 潤滑油組成物
US8715665B2 (en) * 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
EP2271943A1 (en) * 2008-04-29 2011-01-12 Novartis AG Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
EP2288383A1 (en) * 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
US20140057908A1 (en) * 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEX KENTSIS ETAL: "Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition", 《BLOOD(ASH ANNUAL MEETING ABSTRACTS)》 *

Also Published As

Publication number Publication date
RU2014143213A (ru) 2016-05-27
WO2013151913A1 (en) 2013-10-10
EP2833917A1 (en) 2015-02-11
US20150051210A1 (en) 2015-02-19
CA2866321A1 (en) 2013-10-10
KR20140146086A (ko) 2014-12-24
JP2015512447A (ja) 2015-04-27
MX2014011987A (es) 2014-11-10
AU2013243737B2 (en) 2016-06-30
AU2013243737A1 (en) 2014-09-25
IN2014DN07410A (enExample) 2015-04-24

Similar Documents

Publication Publication Date Title
Yang et al. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
US20190134033A1 (en) Pharmaceutical combinations
JP2022520079A (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
TW202045171A (zh) 包含tno155和瑞博西尼之藥物組合
KR20240024938A (ko) Kras g12c 저해제를 포함하는 약제학적 조합물 및 암의 치료를 위한 이의 용도
EP2834246B1 (en) Combination products with tyrosine kinase inhibitors and their use
Singh et al. Kinases inhibitors in lung cancer: From benchside to bedside
KR20140043314A (ko) 이중 오로라 키나제／ｍｅｋ 억제제를 사용한 항암 치료법
CN105209073A (zh) 包含B-Raf抑制剂和第二抑制剂的组合疗法
WO2023199180A1 (en) Therapeutic uses of a krasg12c inhibitor
JP2024526135A (ja) Ｅｒｋ１／２阻害剤とｋｒａｓ ｇ１２ｃ阻害剤の併用療法
JP2023504046A (ja) ジアリール大環状化合物を含む併用療法
Pattarozzi et al. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells
JP2020529411A (ja) 第三世代ｅｇｆｒチロシンキナーゼ阻害剤とｒａｆ阻害剤の治療用組合せ
AU2013243737B2 (en) Tyrosine kinase inhibitor combinations and their use
JP2023524789A (ja) Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ
US20250032458A1 (en) Treatment of cancer with an fgfr kinase inhibitor
Zhang et al. Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future
ES2855075T3 (es) Combinación de ceritinib con un inhibidor de EGFR
CN121038792A (zh) 用met激酶抑制剂治疗癌症
Esdar et al. M4205 (IDRX-42) is a highly selective and potent inhibitor of relevant oncogenic driver and resistance variants of KIT in cancer
EP2608793B1 (en) Use of a receptor-type kinase modulator for treating polycystic kidney disease
WO2025111339A1 (en) Treatment of cancer with a parg inhibitor
Schellens et al. 564 POSTER First-in-human (FIH) study of PF-00299804 in advanced cancer patients: correlation between pharmacokinetics (PK) and pharmacodynamics (PD)
EA040191B1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141224